The clinical value of circulating free tumor DNA in testicular germ cell tumor patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F22%3A43923676" target="_blank" >RIV/00064173:_____/22:43923676 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/22:10444738 RIV/00216208:11110/22:10444738 RIV/00216208:11120/22:43923676 RIV/00216208:11130/22:10444738 RIV/00064190:_____/22:N0000032

Result on the web

<a href="https://doi.org/10.1016/j.urolonc.2022.04.021" target="_blank" >https://doi.org/10.1016/j.urolonc.2022.04.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.urolonc.2022.04.021" target="_blank" >10.1016/j.urolonc.2022.04.021</a>

Result language

angličtina

Original language name

The clinical value of circulating free tumor DNA in testicular germ cell tumor patients

Original language description

BACKGROUND: Testicular germ cell tumors (TGCT) are unique malignancies of young adult men; their biology is, however, underexplored and there has not been much progress in their treatment for decades. Circulating free tumor DNA (cfDNA) analysis represents a promising way of discovering novel diagnostic and treatment options. OBJECTIVE: The study evaluates the clinical value of cfDNA detection in TGCT patients. DESIGN AND METHODS: Total cfDNA concentration and ratio of its 2 main fragments (180 and 360 bp) were evaluated by spectrophotometry, capillary electrophoresis and qPCR in peripheral blood plasma of 96 TGCT patients (173 samples) and 31 normal controls. Non-parametric tests were used for statistical analyses. RESULTS: The total cfDNA concentration was significantly higher in TGCT than in controls (P &lt; 0.0001), with the highest levels at disease progression, but with no clear threshold between malignant and normal samples. Patients with positive tumor markers had higher cfDNA concentrations than those with negative markers (P = 0.01). Longer 360 bp cfDNA fragments were found in 58% of TGCT patients including almost all samples from relapse or disease progression but no normal controls (P &lt; 0.0001). CONCLUSION: Total cfDNA levels are significantly increased in TGCT patients but without a clear threshold separating normal and tumor samples, thus total cfDNA amount itself is not a sensitive enough marker to identify or monitor TGCT. Longer cfDNA fragments have been found exclusively in a proportion of tumors and predominantly at disease progression, representing a novel potential marker for TGCT monitoring that would deserve further exploration.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/LM2015091" target="_blank" >LM2015091: National Center for Medical Genomic</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Urologic Oncology

ISSN

1078-1439

e-ISSN

1873-2496

Volume of the periodical

40

Issue of the periodical within the volume

9

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

"412.e15"-"412.e24"

UT code for WoS article

000862850200020

EID of the result in the Scopus database

2-s2.0-85132521301